[Assessment of efficacy and tolerance of tanakan during treatment of sensorineural bradyacuasia and tympanophonia].
The objective of the study was to evaluate efficacy and tolerance of tanakan during treatment of neurosensory hearing loss and subjective tinnitis supposedly of vascular etiology. The secondary purpose was to analyse late results of 3 month courses of therapy and changes in the clinical course of the disease during treatment and within 6 months after its termination. Tanakan was first given at a dose of 40 mg thrice daily for 90 days. Results of the treatment were estimated on days 90, 180, and 240. The second course (40 mg thrice daily for 90 days) was initiated 180 days after the end of the first one. The final outcome was evaluated on day 360. It was shown that monotherapy with tanakan effectively improved the hearing function and had the most pronounced beneficial effect on subjective tinnitus. Results of the treatment remained stable throughout the entire observation period (12 months).
Kunel'skaia
N L
NL
Levina
Iu V
IuV
Krasiuk
A A
AA
Doronina
O M
OM
D000328:Adult; D000368:Aged; D001301:Audiometry, Pure-Tone; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D020441:Ginkgo biloba; D046934:Ginkgolides; D006309:Hearing / Q000187:drug effects / Q000502:physiology; D006319:Hearing Loss, Sensorineural / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D008297:Male; D008875:Middle Aged; D010936:Plant Extracts / Q000008:administration & dosage / Q000627:therapeutic use*; D013997:Time Factors; D014012:Tinnitus / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D016896:Treatment Outcome; D055815:Young Adult; D000096983:Ginkgo Extract
D046934:Ginkgolides; D010936:Plant Extracts; C063170:Ginkgo biloba extract; D000096983:Ginkgo Extract